Want to join the conversation?
$BMY 2Q15 Call: Over next five years, expects growth to come primarily from Opdivo and Eliquis with contribution from the rest of existing portfolio of medicines. Announced today that European Commission validated two Opdivo applications; one for non-squamous cell lung cancer and two in combination with Yervoy for Metastatic Melanoma.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.